Equities

Mallinckrodt Plc

Mallinckrodt Plc

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (USD)29.68
  • Today's Change-0.11 / -0.37%
  • Shares traded1.36m
  • 1 Year change-12.89%
  • Beta1.5957
Data delayed at least 15 minutes, as of Sep 19 2018 21:02 BST.
More ▼

Profile data is unavailable for this security.

About the company

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

  • Revenue in USD (TTM)2.79bn
  • Net income in USD1.14bn
  • Incorporated2013
  • Employees3.90k
  • Location
    Mallinckrodt Plc3 Lotus Park, The CausewaySTAINES TW18 3AGUnited KingdomGBR
  • Phone+44 17 8463 6700
  • Websitehttp://mallinckrodt.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MNK:NYQ since
announced
Transaction
value
Sucampo Pharmaceuticals IncDeal completed26 Dec 201726 Dec 2017Deal completed27.27%882.22m
Ocera Therapeutics IncDeal completed02 Nov 201702 Nov 2017Deal completed-7.42%108.71m
Data delayed at least 15 minutes, as of Sep 19 2018 21:02 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DSwiss Inc240.52k-319.50k517.26m7.00--1,312.68--2,150.60-0.0015-0.00150.00120.00190.3752.7520.5034,360.00-49.81---57.51--51.44---132.84--6.97--0.00--32.24--44.79------
Luckwel Pharmaceuticals Inc0.00-600.14k716.88m-----------0.0229-0.02290.00-0.00270.00-------324.35-533.54-------------------------5.17------
Diplomat Pharmacy Inc5.04bn-4.69m1.48bn2.18k--1.9518.990.2942-0.06310.048270.1610.203.4526.7116.012,314,464.00-0.32690.9507-0.48161.667.707.29-0.09460.22250.62870.78530.43760.001.7031.82-72.83--18.65--
TRHF Company Ltd Inc82.14k-442.14k1.53bn----5.02--18,626.73-0.0007-0.00070.00010.50780.000310.2953.17---0.175---0.1752--62.47---538.28--0.0079--0.3963--6.82---93.99------
Mallinckrodt PLC2.79bn1.14bn2.47bn3.90k2.410.38091.270.88512.2918.0631.1377.910.18815.256.81715,512.807.71--8.34--50.72--40.99--2.061.070.4954--------------
Heron Therapeutics Inc47.47m-195.29m2.62bn145.00--6.07--55.19-3.20-3.200.76425.560.14540.67211.47327,372.40-59.82-119.24-74.26-161.9877.35---411.41-1,871.906.04-174.190.0632--2,305.55---14.06--21.30--
Data as of Sep 19 2018. Currency figures normalised to Mallinckrodt Plc's reporting currency: US Dollar USD

Institutional shareholders

61.57%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20188.84m10.62%
Scopia Capital Management LPas of 30 Jun 20187.67m9.22%
The Vanguard Group, Inc.as of 30 Jun 20187.33m8.81%
Deerfield Management Company LPas of 30 Jun 20186.99m8.40%
Dimensional Fund Advisors LPas of 30 Jun 20184.42m5.32%
SSgA Funds Management, Inc.as of 30 Jun 20183.69m4.43%
Paulson & Co., Inc.as of 30 Jun 20183.67m4.41%
Miller Value Partners LLCas of 30 Jun 20183.34m4.01%
LSV Asset Managementas of 30 Jun 20182.68m3.22%
Hotchkis & Wiley Capital Management LLCas of 30 Jun 20182.61m3.13%
More ▼
Data from 30 Jun 2018 - 30 Jun 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.